Donate For Public and Patients Store Search

U086 - Merkel Cell Carcinoma: Diagnosis, Management, and Controversies

Monday, March 4; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Utilize recent developments in the clinical management of Merkel cell carcinoma, including sentinel lymph node biopsy, adjuvant therapy, and systemic therapy to guide multidisciplinary care of patients with MCC.
  • Identify areas of consensus and controversy regarding the clinical management of MCC.


Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma with a higher disease-specific mortality than melanoma. MCC is rare, but the incidence is increasing in the US. Clinical management is challenging due to lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and encouraged by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. This session will focus on current concepts in the diagnosis and management of MCC.


  • Harms, Kelly L, MD, PhD: no financial relationships exist with commercial interests.
Monday, March 4
4:30 PM
Dr. Harms / Merkel Cell Carcinoma: Diagnosis, Management, and Controversies
Event Details
  • Date
    Monday, March 4
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 140B
  • CME Credits
  • Type
  • Kelly L Harms, MD, PhD, FAAD